摘要
肿瘤坏死因子(TNF )与葡萄膜炎的发生发展密切相关,成为免疫抑制治疗的靶点,抗TNF生物制剂应用于临床,可望超越常规药物的疗效,并可避免严重副作用。本文就目前该类药物的制剂类型、作用机制、疗效、副作用的基础和临床研究进展作一综述。
出处
《国外医学（眼科学分册）》
2005年第2期93-96,共4页
Foreign Medical Sciences(Section of Ophthalmology )
参考文献21
-
1Smith JR, Levinson RD, Holland GN, et al. Differential efficacy of TNF inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritis Rheum, 2001, 45: 252-257.
-
2de Kozak Y, Verwaerde C. Cytokines in immunotherapy of experimental uveitis. Int Rev Immunol, 2002, 21:231-253.
-
3Dick AD, Isaacs JD. Immunomodulation of autoimmune responses with monoclonal antibodies and immunoadhesins:treatment of ocular inflammatory disease in the next millennium. Br J Ophthalmol,1999, 83:1230- 1234.
-
4Boyd SR, Young S, Lightman S, et al. Immunopathology of the noninfectious posterior and intermediate uveitis. Surv Ophthalmol,2001,46:209-233.
-
5Santos Lacomba M, Marcos Martin C, Gallardo Galera JM, et al. Aqueous humor and serum tumor necrosis factor-alpha in clinical uveitis. Ophthalmic Res, 2001,33:251-255.
-
6Perez-Guijo V, Santos-Lacomba M, Sanchez-Heruandez M, et al.Tumor necrosis factor-alpha levels in aqueous humour and serum from patients with uveitis: the involvement of HLA-B27. Curr Med Res Opin, 2004,20:155-157.
-
7Murphy CC, Duncan L, Forrester JV, et al. Systemic CD4 + T cell phenotype and activation status in intermediate uveitis. Br J Ophthalmol, 2004,88:412-416.
-
8Sfikakis PP, Theodossiadis PG, Katsiari CG, et al. Effect of infliximab on sight-threatening panuveitis in Behcet's disease. Lancet,2001,358:295-296.
-
9Greiner K, Murphy CC, Willermain F, et al. Anti-TNFalpha therapy modulates the phenotype of peripheral blood CD4 + T cells in patients with posterior segment intraocular inflammation. Invest Ophthalmol Vis Sci, 2004, 45:170-176.
-
10Robertson M, Liversidge J, Forrester JV, et al. Neutralizing tumor necrosis factor-alpha activity suppresses activation of infiltrating macrophages in experimental autoimmune uveoretinitis. Invest Ophthalmol Vis Sci, 2003, 44:3034-3041.
同被引文献11
-
1郑曰忠,原莉莉,林锦镛,李会强.经鼻黏膜诱导免疫耐受治疗实验性自身免疫性葡萄膜炎[J].中华眼科杂志,2006,42(12):1118-1122. 被引量：3
-
2沈降,孙慧敏,田恩江.抗肿瘤坏死因子-α治疗葡萄膜炎的研究现状[J].国外医学（眼科学分册）,2005,29(2):96-99. 被引量：5
-
3张海男,黎杏群,李学文.清肝泻火汤对内毒素诱发家兔肝火证的疗效和机理[J].中国中西医结合杂志,1996,16(2):95-98. 被引量：19
-
4ZHANG Rui,YANG Pei-zeng,WU Chang-you,JIN Hao-li,LI Bing,HUANG Xiang-kun,ZHOU Hong-yan,GAO Yang,ZHU Lian-xiang,Aize Kijlstra.Role of T-cell receptor V beta 8.3 peptide vaccine in the prevention of experimental autoimmune uveoretinitis[J].Chinese Medical Journal,2006(9):740-748. 被引量：9
-
5刘相东,孙善会,肖东杰,牟国营,汪运山.白细胞介素-1受体拮抗剂基因型2/2与白塞病葡萄膜炎易感性的相关研究[J].山东大学学报（医学版）,2007,45(5):467-469. 被引量：7
-
6样倍增.葡萄膜炎诊断与治疗[M].北京:人民卫生出版社,2009:48.
-
7E1-Shabrawi Y,Wegscheider B J,Weger M,et al.Polmyorphisms within the tumo rnecrosis factor-alpha promoterregion in patientswiht HLA-B27-associated uveitis:association with susceptibility and clinical manifestations[J].Ophhtalmology,2006,113 (4):695.
-
8Spagnol P,Sato H,Marshall S E,et al.Association between heat shcok protein 70/Hom genetic polymorphisms and uveitis in patients with sarcoidosis[J].Invest Ophthlamol Vis Sci,2007,48 (7):3019.
-
9Mizuk N,Meguro A,Tohnai I,et al.Association of major histcoompatibility complex class Ⅰ chain-related geneA and HLA-B alleles with Behcet's disesae in Turkey[J].Jpn J Ophthalmol,2007,51 (6):431.
-
10肖哲夫,夏远春,曾明葵.抑阳酒连散对急性葡萄膜炎模型大鼠房水及外周血TNF-α的影响[J].中医药导报,2009,15(3):69-71. 被引量：12
二级引证文献11
-
1陈海婷,王红.生物制剂在葡萄膜炎治疗中的应用[J].眼科新进展,2010,30(5):481-485. 被引量：2
-
2郑曰忠.重视葡萄膜炎药物治疗研究，提高葡萄膜炎药物治疗效果[J].中华眼底病杂志,2010,26(5):404-408. 被引量：9
-
3王婧,卢弘.Toll样受体-4及其介导的信号转导与急性前葡萄膜炎[J].眼科新进展,2011,31(10):987-990. 被引量：3
-
4何旭,普小菲,李娇,彭芳.美洲大蠊提取物对S180荷瘤小鼠肿瘤抑制作用及免疫功能的影响[J].中国实验方剂学杂志,2012,18(15):179-182. 被引量：30
-
5李燕利,杨炜.葡萄膜炎的生物治疗进展[J].国际眼科杂志,2013,13(6):1147-1151. 被引量：3
-
6叶延程,赵良存,李少海,王学满,白春香,王学习.舒尔通合剂抗炎、镇痛作用的实验研究[J].中国中医药科技,2013,20(4):350-351.
-
7张莲,毕宏生,郭俊国.抗TNF生物制剂在葡萄膜炎临床治疗中的应用进展[J].眼科新进展,2014,34(12):1187-1189. 被引量：5
-
8白琳,杨培增.白塞病葡萄膜炎的治疗与展望[J].中华实验眼科杂志,2016,34(8):761-764. 被引量：3
-
9蒋红芬,蒋秋儿.穴位埋线治疗顽固性葡萄膜炎临床观察[J].新中医,2017,49(2):141-143. 被引量：3
-
10柳琳,卢弘.肿瘤坏死因子α抑制剂在幼年特发性关节炎相关性葡萄膜炎中的应用进展[J].中华眼底病杂志,2021,37(5):399-403. 被引量：2
-
1肿瘤坏死因子在类风湿关节炎发病机制中的作用和抗肿瘤坏死因子制剂的作用机制[J].中华风湿病学杂志,2010,14(6):440-440. 被引量：1
-
2抗肿瘤坏死因子制剂(Anti-TNF)[J].海峡预防医学杂志,2004,10(1):7-7.
-
3严炎中,徐雯宇,娄牡英.国内凝胶制剂的研究概况[J].医药导报,2004,23(12):937-938. 被引量：4
-
4徐梅英.临床医师在胰岛素合理应用中应注意的几个问题[J].内蒙古中医药,2013(10):70-70. 被引量：2
-
5卓新凤.中药制剂的不良反应分析[J].西部中医药,2014,27(1):42-43. 被引量：6
-
6赵征,黄烽.抗肿瘤坏死因子制剂治疗脊柱关节病[J].军医进修学院学报,2004,25(6):459-460.
-
7黄敏燕.研究支持抗肿瘤坏死因子治疗强直性脊椎炎[J].国外药讯,2005(7):29-30.
-
8英利昔单抗改善活动性银屑病关节炎患者的生活状态[J].新医学,2006,37(9):562-562.
-
9许婷婷,邢爱敏.抗肿瘤坏死因子制剂Golimumab对中重度活动性溃疡性结肠炎有临床疗效[J].药学进展,2012,36(6):286-286.
-
10黄胜炎.抗癫痫药新制剂类型与疗效[J].上海医药,2006,27(10):457-459.
